165 related articles for article (PubMed ID: 37106324)
1. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
[TBL] [Abstract][Full Text] [Related]
2. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
4. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
5. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Loibl S; Darb-Esfahani S; Huober J; Klimowicz A; Furlanetto J; Lederer B; Hartmann A; Eidtmann H; Pfitzner B; Fasching PA; Tiemann K; Jackisch C; Mehta K; von Minckwitz G; Untch M; Denkert C
Clin Cancer Res; 2016 Jun; 22(11):2675-83. PubMed ID: 26758558
[TBL] [Abstract][Full Text] [Related]
6. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Xu B; Guan Z; Shen Z; Tong Z; Jiang Z; Yang J; DeSilvio M; Russo M; Leigh M; Ellis C
Breast Cancer Res; 2014 Jul; 16(4):405. PubMed ID: 25056500
[TBL] [Abstract][Full Text] [Related]
7. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Wang Y; Liu Y; Du Y; Yin W; Lu J
Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
Jensen JD; Knoop A; Laenkholm AV; Grauslund M; Jensen MB; Santoni-Rugiu E; Andersson M; Ewertz M
Ann Oncol; 2012 Aug; 23(8):2034-2042. PubMed ID: 22172323
[TBL] [Abstract][Full Text] [Related]
9. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
12. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
[TBL] [Abstract][Full Text] [Related]
13. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
[TBL] [Abstract][Full Text] [Related]
14. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Skriver SK; Jensen MB; Eriksen JO; Ahlborn LB; Knoop AS; Rossing M; Ejlertsen B; Laenkholm AV
Breast Cancer Res Treat; 2020 Nov; 184(1):123-133. PubMed ID: 32748297
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Guo S; Loibl S; von Minckwitz G; Darb-Esfahani S; Lederer B; Denkert C
Cancer Res Treat; 2020 Jul; 52(3):689-696. PubMed ID: 32019278
[TBL] [Abstract][Full Text] [Related]
16. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
[TBL] [Abstract][Full Text] [Related]
18. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
19. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.
Fan H; Li C; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Zhou Y; Zhao X; Cui Y
Thorac Cancer; 2018 May; 9(5):571-579. PubMed ID: 29575819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
